Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE versus NIPRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE versus NIPRIDE.
Hydralazine vs NIPRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased peripheral vascular resistance and blood pressure. Its exact mechanism is unclear but may involve interference with calcium movement and increased cGMP levels.
Nipride (sodium nitroprusside) is a potent vasodilator that acts directly on vascular smooth muscle, both arterial and venous, by releasing nitric oxide (NO). Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels, leading to relaxation of smooth muscle and subsequent reduction in peripheral vascular resistance and blood pressure.
10-50 mg orally every 6 hours, titrate to maximum 300 mg/day; 10-20 mg intramuscularly or intravenously every 4-6 hours as needed.
Intravenous infusion: initial 0.3-0.5 mcg/kg/min, titrate up to 10 mcg/kg/min as needed.
None Documented
None Documented
Clinical Note
moderateHydralazine + Benzydamine
"Hydralazine may decrease the antihypertensive activities of Benzydamine."
Clinical Note
moderateHydralazine + Droxicam
"Hydralazine may decrease the antihypertensive activities of Droxicam."
Clinical Note
moderateHydralazine + Loxoprofen
"Hydralazine may decrease the antihypertensive activities of Loxoprofen."
Clinical Note
moderateHydralazine + Clonixin
"Hydralazine may decrease the antihypertensive activities of Clonixin."
The terminal elimination half-life of hydralazine is approximately 2-4 hours in patients with normal renal function. However, the duration of antihypertensive effect may be longer (6-12 hours) due to tissue binding and slow release from vascular smooth muscle. In renal impairment, half-life may extend to 7-16 hours, necessitating dose adjustment.
Nitroprusside: ~2 minutes (converted to cyanide); cyanide (as thiocyanate): 2.7 days; clinical context: continuous IV infusion required; thiocyanate accumulation risk in renal impairment.
Hydralazine is primarily metabolized in the liver via N-acetylation and hydroxylation. Approximately 80-90% of the drug is eliminated in urine as metabolites, with less than 10% excreted unchanged. A small fraction appears in feces via biliary excretion.
Renal: ~50% as unchanged drug; hepatic metabolism to thiocyanate, which is renally eliminated (half-life 2-3 days); <1% fecal.
Category A/B
Category C
Vasodilator
Vasodilator